Clinical Scorecard: Utilizing Brain MRI and FDG-PET for Diagnosing Neurodegenerative Disorders

At a Glance

Key Highlights

• Brain MRI is essential for structural assessment and exclusion of mimicking diseases in cognitive impairment.
• FDG-PET/CT complements MRI by detecting regional brain metabolism changes aiding differential diagnosis of dementias.
• Specific MRI features include white matter hyperintensities (WMH), sulcal/ventricular dilatation patterns, and microhemorrhages.

Guideline-Based Recommendations

Diagnosis

• Perform brain MRI with sequences including T2-weighted, T2 FLAIR, diffusion-weighted, SWI, and high-resolution 3D T1-weighted imaging for volumetric analysis.
• Assess MRI for extent of microvascular ischemic disease using Fazekas scale, sulcal and ventricular dilatation patterns, regional brain atrophy, and presence of microhemorrhages or superficial siderosis.
• Use FDG-PET/CT after 6 hours fasting with 18F-Fluorodeoxyglucose injection and 3D-SSP statistical mapping to identify abnormal metabolic patterns.
• Consider amyloid PET to detect amyloid pathology for Alzheimer disease diagnosis and treatment eligibility.

Management

• Use imaging findings to guide differential diagnosis among neurodegenerative disorders and vascular contributions to cognitive impairment.
• Evaluate for normal pressure hydrocephalus (NPH) in patients with characteristic imaging and clinical triad; consider high-volume lumbar puncture to predict shunt responsiveness.

Monitoring & Follow-up

• Quantitative volumetric MRI analysis can be used to monitor brain atrophy progression compared to age-matched controls.
• Follow-up imaging may assess progression of white matter hyperintensities and microvascular ischemic disease.

Risks

• Microvascular ischemic disease is associated with vascular risk factors including hypertension, hyperlipidemia, diabetes, stroke history, and smoking.
• Cerebral amyloid angiopathy suggested by microhemorrhages or superficial siderosis increases risk of hemorrhagic complications.

Patient & Prescribing Data

Elderly patients with cognitive impairment or suspected dementia undergoing diagnostic imaging

Imaging findings support diagnosis and eligibility for anti-amyloid treatments and guide management decisions including shunt placement in NPH.

Clinical Best Practices

• Incorporate comprehensive brain MRI sequences including high-resolution 3D T1-weighted imaging for volumetric assessment.
• Use standardized scales such as Fazekas for white matter hyperintensity evaluation to correlate with cognitive status.
• Combine MRI and FDG-PET/CT findings for improved diagnostic accuracy in differentiating neurodegenerative disorders.
• Assess for imaging signs of NPH and perform clinical correlation with lumbar puncture testing to guide treatment.
• Exclude structural mimics of dementia through detailed imaging assessment.

References

• Alzheimer's Disease International Dementia Statistics
• Meta VCI Map Consortium Study on WMH and Post-Stroke Cognitive Function
• Fazekas Scale for White Matter Hyperintensity Assessment
• 3D-SSP Statistical Mapping for FDG-PET/CT
• Imaging Features of Normal Pressure Hydrocephalus and DESH